Linked Life Data

21076538

Source:http://linkedlifedata.com/resource/pubmed/id/21076538

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2010-11-15
pubmed:abstractText
Cancer is the second leading cause of death in the world after cardiovascular diseases. Some types of cancer cells often travel to other parts of the body through blood circulation or lymph vessels, where they begin to grow. This process is recognized as metastasis. Angiogenesis is the formation of new blood vessels from existing vessel. Normally angiogenesis is a healthy process, that helps the body to heal wounds and repair damaged body tissues, whereas in cancerous condition this process supports new blood vessels formation that provide a tumor with its own blood supply, nutrients and allow it to grow. The most important proximal factor for angiogenesis is the vascular endothelial growth factor VEGF. Angioinhibition is a form of targeted therapy that uses drugs to stop tumors from making new blood vessels. Therefore, in this paper we analyse the importance of VEGF as target of cancer therapy, analysing murine models.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1110-7251
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
2011
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
947928
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Anti-VEGF therapy in breast and lung mouse models of cancers.
pubmed:affiliation
Dipartimento di Patologia Generale, Seconda Università degli Studi di Napoli, Napoli, Italy. marina.didomenico@unina2.it
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't